News + Publications
Board of Directors + Governance
Health Impact Reports
Accelerating Medicines Partnership® (AMP®)
Accelerating COVID-19 Therapeutic Interventions & Vaccines (ACTIV)
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
GeneConvene Global Collaborative
Azithromycin Prevention in Labor Use Study (A-PLUS)
Master Protocol for Treatment of Non-Small Cell Lung Cancer (Lung-MAP)
Partnership For Accelerating Cancer Therapies (PACT)
Edmond J. Safra Family Lodge
Global Pandemic Treaty
All of Us Research Program
Education & Training Programs
Inflammation + Immunology
Maternal, Child + Newborn Health
FNIH Awards Ceremony
The Lurie Prize in Biomedical Sciences
Trailblazer Prize for Clinician-Scientists
Charles A. Sanders, MD Partnership Award
The Deeda Blair Research Initiative for Disorders of the Brain
Fellowships & Training
Partner With Us
Awards & Prizes
Fellowship & Training
Fighting Diseases (Research)
Acute Myeloid Leukemia (AML)
Adult Acute Lymphoblastic Leukemia (ALL)
Cell and Gene Therapy
Genetics and Genomics
Inflammation and Immunology
Native American health
Neglected Tropical Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Non-Alcoholic Steatohepatitis (NASH)
Opioid Use Disorder
Displaying 1 - 7 of 7
Biomarkers Consortium – Treatments Against RA and Effect on FDG PET-CT (TARGET Biomarker Study)
The Problem Rheumatoid arthritis (RA) is currently difficult to treat and people with RA are at increased risk for developing cardiovascula...
Biomarkers Consortium – Mucosal Healing in UC: Definition, Treatment Target and Clinical Endpoints
The Problem Mucosal healing is an important outcome in clinical trials of drugs to treat ulcerative colitis, yet Researchers lack a standar...
Biomarkers Consortium – PROGRESS OA: Clinical Evaluation and Qualification of Osteoarthritis Biomarkers
Overview The Biomarkers Consortium’s PROGRESS OA - Clinical Evaluation and Qualification of Osteoarthritis Biomarkers Project is the seco...
Biomarkers Consortium – Clinical Evaluation and Qualification of Translational Kidney Safety Biomarkers
The Problem When conducting clinical trials of any drugs that could cause acute kidney injury, Researchers need biomarkers that can detect ...
Biomarkers Consortium – Developing Endpoints for Clinical Trials in Community Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Infections (ABSSSI)
The Problem To develop effective treatments for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection...
Accelerating Medicines Partnership® Program – Rheumatoid Arthritis, Systemic Lupus Erythematosus
The Problem Autoimmune disorders such as Rheumatoid Arthritis and Systemic Lupus Erythematosus are biologically complex; understanding the ...
AMP Autoimmune & Immune-Mediated Diseases
The Accelerating Medicines Partnership® (AMP®) Program Autoimmune and Immune-Mediated Diseases (AMP AIM) is a precompetitive partnership t...
Partner With Us